Renaissance Technologies's BBIO Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 322,246 shares of BridgeBio Pharma, Inc. (BBIO) worth $16.74 M, representing 0.02% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in BBIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2022, adding 953,500 shares. Largest reduction occurred in Q2 2025, reducing 338,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's BridgeBio Pharma (BBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly BridgeBio Pharma (BBIO) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2021 | +118,546 | New Buy | 118,546 | $61.60 |
| Q2 2021 | -118,546 | Sold Out | 118,546 | $0.00 |
| Q2 2022 | +413,246 | New Buy | 413,246 | $9.08 |
| Q3 2022 | +953,500 | Add 230.73% | 1.37 M | $9.94 |
| Q4 2022 | -336,800 | Reduce 24.64% | 1.03 M | $0.01 |
| Q1 2023 | -266,200 | Reduce 25.85% | 763,746 | $0.02 |
| Q2 2023 | -763,746 | Sold Out | 763,746 | $0.00 |
| Q3 2023 | +584,146 | New Buy | 584,146 | $26.37 |
| Q4 2023 | -584,146 | Sold Out | 584,146 | $0.00 |
| Q2 2025 | +245,946 | New Buy | 245,946 | $43.18 |
| Q3 2025 | +76,300 | Add 31.02% | 322,246 | $51.94 |
Renaissance Technologies's BridgeBio Pharma Investment FAQs
Renaissance Technologies first purchased BridgeBio Pharma, Inc. (BBIO) in Q1 2021, acquiring 118,546 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held BridgeBio Pharma, Inc. (BBIO) for 19 quarters since Q1 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to BridgeBio Pharma, Inc. (BBIO) was in Q3 2022, adding 1,366,746 shares worth $13.58 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 322,246 shares of BridgeBio Pharma, Inc. (BBIO), valued at approximately $16.74 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BridgeBio Pharma, Inc. (BBIO) represents approximately 0.02% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in BridgeBio Pharma, Inc. (BBIO) was 1,366,746 shares, as reported at the end of Q3 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.